OncoCyte (OCX) Presents Positive Results from R&D Validation Study of DetermaVu at ATS
Tweet Send to a Friend
OncoCyte Corporation (NYSE: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today presented results from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE